By Admin at 13 Oct 2016

About 5 percent of breast cancer patients develop cancer in the other breast (contralateral breast cancer) within 10 years of their initial diagnosis. Drugs including tamoxifen and aromatase inhibitors are often prescribed to patients to reduce this risk, but researchers from the U.S. National Institutes of Health wanted to find out just how beneficial the drugs were in real-life settings.